Protein Kinase B and Extracellular Signal-Regulated Kinase Inactivation is Associated with Regorafenib-Induced Inhibition of Osteosarcoma Progression In Vitro and In Vivo

Osteosarcoma is the most common type of bone cancer. Multimodality treatment involving chemotherapy, radiotherapy and surgery is not effective enough to control osteosarcoma. Regorafenib, the oral multi-kinase inhibitor, has been shown to have positive efficacy on disease progression delay in chemot...

Descripción completa

Detalles Bibliográficos
Autores principales: Pan, Po-Jung, Liu, Yu-Chang, Hsu, Fei-Ting
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2019
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6616516/
https://www.ncbi.nlm.nih.gov/pubmed/31238539
http://dx.doi.org/10.3390/jcm8060900

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6616516/
https://www.ncbi.nlm.nih.gov/pubmed/31238539
http://dx.doi.org/10.3390/jcm8060900

Ejemplares similares